{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:03:26Z","timestamp":1781013806542,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11060-026-05602-7","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:17:44Z","timestamp":1779268664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment patterns and outcomes in high-risk WHO grade 2 diffuse glioma: a multicentre retrospective cohort study"],"prefix":"10.1007","volume":"178","author":[{"given":"Jason L.","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Alshamsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Andronic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hely","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Leigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikayla","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jane","family":"Lim Fat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathie","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manik","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marya","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria Roldan","family":"Urgoiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"8","key":"5602_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of Tumors of the central Nervous System: a summary. Neuro-Oncology 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro-Oncology"},{"issue":"25","key":"5602_CR2","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.2011.35.8598","volume":"30","author":"EG Shaw","year":"2012","unstructured":"Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP (2012) Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. JCO 30(25):3065\u20133070. https:\/\/doi.org\/10.1200\/JCO.2011.35.8598.","journal-title":"JCO"},{"issue":"18","key":"5602_CR3","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1200\/JCO-25-00250","volume":"43","author":"J Blakeley","year":"2025","unstructured":"Blakeley J, Mohile NA, Messersmith H, Lassman AB, Schiff D, Blakeley J, Gatson NT, Hottinger AF, Lassman A, Mohile NA, Morton J, Ney D, Nghiemphu PL, Perry J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M (2025) Therapy for diffuse astrocytic and oligodendroglial Tumors in adults: ASCO-SNO guideline rapid recommendation update. JCO 43(18):2129\u20132133. https:\/\/doi.org\/10.1200\/JCO-25-00250.","journal-title":"JCO"},{"issue":"14","key":"5602_CR4","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","volume":"374","author":"JC Buckner","year":"2016","unstructured":"Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary J-P, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 374(14):1344\u20131355. https:\/\/doi.org\/10.1056\/NEJMoa1500925.","journal-title":"N Engl J Med"},{"issue":"29","key":"5602_CR5","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/JCO.19.02983","volume":"38","author":"EH Bell","year":"2020","unstructured":"Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Won M, Chakravarti A (2020) Comprehensive Genomic analysis in NRG Oncology\/RTOG 9802: a Phase III trial of Radiation versus Radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. JCO 38(29):3407\u20133417. https:\/\/doi.org\/10.1200\/JCO.19.02983.","journal-title":"JCO"},{"issue":"4","key":"5602_CR6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ijrobp.2020.03.027","volume":"107","author":"BJ Fisher","year":"2020","unstructured":"Fisher BJ, Pugh SL, Macdonald DR, Chakravatri A, Lesser GJ, Fox S, Rogers CL, Werner-Wasik M, Doyle T, Bahary J-P, Fiveash JB, Bovi JA, Howard SP, Michael Yu H-H, D\u2019Souza D, Laack NN, Barani IJ, Kwok Y, Wahl DR, Strasser JF, Won M, Mehta MP (2020) Phase 2 study of a temozolomide-based Chemoradiation therapy regimen for high-risk, Low-Grade Gliomas: long-term results of Radiation therapy Oncology group 0424. Int J Multiling Radiat Oncol*Biol*Phys 107(4):720\u2013725. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.03.027.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"3","key":"5602_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-006-9280-4","volume":"82","author":"N Pouratian","year":"2007","unstructured":"Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D (2007) Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 82(3):281\u2013288. https:\/\/doi.org\/10.1007\/s11060-006-9280-4.","journal-title":"J Neurooncol"},{"issue":"3","key":"5602_CR8","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s10143-020-01326-y","volume":"44","author":"J Wang","year":"2021","unstructured":"Wang J, Yan L, Ai P, He Y, Guan H, Wei Z, He L, Mu X, Liu Y, Peng X (2021) Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study. Neurosurg Rev 44(3):1447\u20131455. https:\/\/doi.org\/10.1007\/s10143-020-01326-y.","journal-title":"Neurosurg Rev"},{"key":"5602_CR9","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.2147\/OTT.S108989","volume":"9","author":"X-J Gai","year":"2016","unstructured":"Gai X-J, Wei Y-M, Tao H-M, An D-Z, Sun J-T, Li B (2016) Comparison of long-term survival between temozolomide-based chemoradiotherapy and radiotherapy alone for patients with low-grade gliomas after surgical resection. OTT 9:5117\u20135121. https:\/\/doi.org\/10.2147\/OTT.S108989.","journal-title":"OTT"},{"key":"5602_CR10","doi-asserted-by":"publisher","unstructured":"Schiff D, O\u2019Neill A, Brown P, Mehta M, Giannini C, Jenkins R, Suh J, Youssef E, Uhm J, Giglio P, Cavaliere R, Moots P, Ashby L, Kleinberg L (2024) LTBK-07. Progression-free and overall survival results of ECOG-ACRIN E3F05: a Phase 3 intergroup trial of radiation \u00b1 temozolomide for grade II GLIOMAS. Neuro-Oncology 26(Supplement_8)viii1-viii2. doi: viii1\u2013viii2. https:\/\/doi.org\/10.1093\/neuonc\/noae165.1303.","DOI":"10.1093\/neuonc\/noae165.1303"},{"key":"5602_CR11","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1 (2026) Fort. National Comprehensive Cancer Network; 2026. Available at: https:\/\/www.nccn.org\/guidelines Washington, PA."},{"issue":"5","key":"5602_CR12","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1200\/PO.21.00112","volume":"5","author":"JL Fleming","year":"2021","unstructured":"Fleming JL, Pugh SL, Fisher BJ, Less GJ, Macdonald DR, Bell EH, McElroy JP, Becker AP, Timmers CD, Aldape KD, Rogers CL, Doyle TJ, Werner-Wasik M, Bahary J-P, Yu H-HM, D\u2019Souza DP, Laack NN, Sneed PK, Kwok Y, Won M, Mehta MP, Chakravarti A (2021) Long-term report of a Comprehensive molecular and Genomic analysis in NRG Oncology\/RTOG 0424: a Phase II study of Radiation and temozolomide in high-risk grade II glioma. JCO Precis Oncol 5(5):1397\u20131407. https:\/\/doi.org\/10.1200\/PO.21.00112.","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"5602_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/neuonc\/noaa168","volume":"23","author":"KA Jaeckle","year":"2021","unstructured":"Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, Cairncross JG, Wick W, Weller M, Aldape KD, Dixon JG, Anderson SK, Cerhan JH, Wefel JS, Klein M, Grossman SA, Schiff D, Raizer JJ, Dhermain F, Nordstrom DG, Flynn PJ, Vogelbaum MA (2021) CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p\/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro-Oncology 23(3):457\u2013467. https:\/\/doi.org\/10.1093\/neuonc\/noaa168.","journal-title":"Neuro-Oncology"},{"key":"5602_CR14","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN (2019) The REDCap consortium: building an international community of software platform partners. J Educ Chang Biomed Inf 95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208.","journal-title":"J Educ Chang Biomed Inf"},{"issue":"9596","key":"5602_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche, von Elm E, G\u00f8tzsche PC, Vandenbroucke JP (2007) The Strengthening the reporting of observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X.","journal-title":"Lancet"},{"issue":"3","key":"5602_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","volume":"31","author":"MJ van den Bent","year":"2013","unstructured":"van den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM, Kouwenhoven MCM, van den Bent MJ, Delattre J-Y, Bernsen HJJA, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WNM, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. JCO 31(3):344\u2013350. https:\/\/doi.org\/10.1200\/JCO.2012.43.2229.","journal-title":"JCO"},{"issue":"3","key":"5602_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","volume":"31","author":"G Cairncross","year":"2013","unstructured":"Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. JCO 31(3):337\u2013343. https:\/\/doi.org\/10.1200\/JCO.2012.43.2674.","journal-title":"JCO"},{"key":"5602_CR18","doi-asserted-by":"publisher","unstructured":"Esteyrie V, Dehais C, Martin E, Carpentier C, Uro-Coste E, Figarella-Branger D, Bronniman C, Pouessel D, Ciron DL, Ducray F, Moyal EC-J, Network P (2021) Radiotherapy plus procarbazine, lomustine, and vincristine versus radiotherapy plus temozolomide for IDH-Mutant anaplastic astrocytoma: a retrospective multicenter analysis of the French POLA cohort. Oncologist 26(5):e838\u2013e846. https:\/\/doi.org\/10.1002\/onco.13701.","DOI":"10.1002\/onco.13701"},{"issue":"3","key":"5602_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.24.00049","volume":"43","author":"SEO Kacimi","year":"2025","unstructured":"Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, Vauleon E, Djelad A, Cohen-Jonathan Moyal E, Langlois O, Campone M, Ducloie M, Noel G, Cuzzubbo S, Taillandier L, Ramirez C, Younan N, Menei P, Dhermain F, Desenclos C, Ghiringhelli F, Bourg V, Ricard D, Faillot T, Appay R, Tabouret E, Nichelli L, Mathon B, Thomas A, Tran S, Bielle F, Alentorn A, Iorgulescu JB, Bo\u00eblle P-Y, Labreche K, Hoang-Xuan K, Sanson M, Idbaih A, Figarella-Branger D, Ducray F et al. (2025) Survival outcomes associated with first-line procarbazine, CCNU, and vincristine or temozolomide in combination with radiotherapy in IDH-Mutant 1p\/19q-codeleted grade 3 oligodendroglioma. JCO 43(3):329\u2013338. https:\/\/doi.org\/10.1200\/JCO.24.00049.","journal-title":"JCO"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05602-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05602-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05602-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:40:16Z","timestamp":1781012416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05602-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5602"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05602-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial interests: Terry L. Ng has received grants from AstraZeneca, speaker and consultant honoraria from Gilead, Novartis, Knight Therapeutics, AstraZeneca, Lilly, and the Canadian Breast Cancer Network. Jennifer Leigh has received speaker honoraria from AstraZeneca. Mary Jane Lim Fat has received consultant honoraria from Servier and Ipsen. Manik Chahal has received honoraria from Servier. Non-financial interests: Terry L. Ng has served on advisory boards for Gilead, Novartis, Knight Therapeutics, AstraZeneca, and Lilly. The remaining authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}